1. Search Result
Search Result
Results for "

FSH

" in MedChemExpress (MCE) Product Catalog:

37

Inhibitors & Agonists

1

Biochemical Assay Reagents

21

Peptides

1

Inhibitory Antibodies

2

Natural
Products

15

Recombinant Proteins

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P4190

    GnRH Receptor Endocrinology
    FSH receptor-binding inhibitor fragment(bi-10) is a potent FSH antagonist. FSH receptor-binding inhibitor fragment(bi-10) blocks the binding of FSH to FSHR, and alteres FSH action at the receptor level. FSH receptor-binding inhibitor fragment(bi-10) results in the suppression of ovulation and causes follicular atresia of mice. FSH receptor-binding inhibitor fragment(bi-10) has the potential for utilizing to restrain the carcinogenesis of ovarian cancer by down-regulating overexpression of FSHR and ERβ in the ovaries .
    Fsh receptor-binding inhibitor fragment(bi-10)
  • HY-118860

    Org 36286; MK-8962

    Estrogen Receptor/ERR Endocrinology
    Corifollitropin alfa (Org 36286) is a long-acting recombinant follicle-stimulating hormone (FSH) analog. Corifollitropin alfa is a FSH Receptor agonist with an EC50 of 5.0 pM. Corifollitropin alfa stimulates ovulation and can be used in the research of infertility .
    Corifollitropin alfa
  • HY-P0056A

    GnRH Receptor Cancer
    Histrelin acetate, a GnRH analogue, is a GnRH Receptor agonist. Histrelin acetate increases serum luteinising hormone (LH), follicle stimulating hormone (FSH) and testosterone levels. Histrelin acetate can be used in the research of prostate cancer, endometriosis .
    Histrelin acetate
  • HY-149105

    Estrogen Receptor/ERR Endocrinology
    FSH receptor antagonist 1 (compound 10) is a potent antagonist of the G(s)-protein-coupled human follicle-stimulating hormone (FSH) receptor. FSH receptor antagonist 1 exhibits an IC50 of 28 nM on a cell line expressing the human FSH receptor. FSH receptor antagonist 1 significantly inhibits follicle growth and ovulation in an ex vivo mouse model .
    FSH receptor antagonist 1
  • HY-P3663

    GnRH Receptor Others
    [Lys8] LH-RH is a analogue of LH-RH. [Lys8] LH-RH stimulates LH and FSH release .
    [Lys8] LH-RH
  • HY-131946

    Menotrophin

    Biochemical Assay Reagents Endocrinology
    Menotropin (Menotrophin) is a hormone that can be extracted from the urine of postmenopausal women and has both follicle stimulating hormone (FSH) and luteinizing hormone (LH) activity .
    Menotropin
  • HY-P3084

    hF-GRP

    GnRH Receptor Endocrinology
    Human follicular gonadotropin releasing peptide (hF-GRP) is a hormone peptide. Human follicular gonadotropin releasing peptide can stimulate pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion in vitro .
    Human follicular gonadotropin releasing peptide
  • HY-P4689

    Estrogen Receptor/ERR Metabolic Disease
    Prolactin-Releasing Peptide (1-31) (rat) is a UHR-1/GRP10 receptor ligand. Prolactin-Releasing Peptide (1-31) (rat) reduces fasting-induced food intake, increases plasma levels of LH, FSH, and testosterone in rats .
    Prolactin-Releasing Peptide (1-31) (rat)
  • HY-105173

    EP 24332

    GnRH Receptor Histamine Receptor Endocrinology Cancer
    Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer .
    Teverelix
  • HY-P0056

    GnRH Receptor Cancer
    Histrelin, a GnRH analogue, is a GnRH Receptor agonist. Histrelin increases serum luteinising hormone (LH), follicle stimulating hormone (FSH) and testosterone levels. Histrelin can be used in the research of prostate cancer, endometriosis .
    Histrelin
  • HY-P1174

    GnRH Receptor Endocrinology
    GnRH Associated Peptide (GAP) (1-13), human is an amino acid peptide fragment derived from GnRH. GAP can increase the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in rat anterior pituitary cells. GAP also inhibit the secretion of prolactin .
    GnRH Associated Peptide (GAP) (1-13), human
  • HY-P3664

    Wy 18185

    GnRH Receptor Endocrinology
    [D-Phe2,D-Ala6]-LH-RH is a potent LH-RH antagonist. [D-Phe2,D-Ala6]-LH-RH shows anti-LH/FSH-RH and antiovulatory activities .
    [D-Phe2,D-Ala6]-LH-RH
  • HY-P3343A
    hFSH-β-(33-53) (TFA)
    1 Publications Verification

    Estrogen Receptor/ERR Cancer
    hFSH-β-(33-53) TFA, a thiol-containing peptide which corresponds to a second FSH receptor-binding domain, is a FSHR (follicle-stimulating hormone receptor) antagonist. hFSH-β-(33-53) TFA inhibits binding of FSH to receptor and is a partial agonist of estradiol synthesis in Sertoli cells .
    hFSH-β-(33-53) (TFA)
  • HY-P2446

    APTAA-LHRH

    GnRH Receptor Endocrinology
    ORG 30276 (APTAA-LHRH) is a potent GnRH antagonist that effectively reduces serum LH and FSH levels in male rats. ORG 30276 significantly decreases unoccupied pituitary GnRH receptors, leading to suppressed gonadotropin secretion. ORG 30276 treatment results in a considerable reduction in mRNA levels of gonadotropin beta-subunits in the pituitary gland. ORG 30276's effects on gonadotropin dynamics can be selectively reversed by the replacement of specific sex steroids, with androgens being particularly effective for the FSH beta-subunit mRNA levels.
    ORG 30276
  • HY-19464

    GnRH Receptor Estrogen Receptor/ERR Endocrinology
    Org 43553 is an orally active and low molecular weight (LMW) luteinizing hormone receptor (LH-R) agonist. Org 43553 shows agonistic activity to human LH and FSH receptors with EC50 values of 3.7 and 110 nM, respectively. Org 43553 can be used for the research of endocrine .
    Org 43553
  • HY-164764

    Estrogen Receptor/ERR Endocrinology
    ADX61623 is a potent follicle stimulating hormone (FSH) receptor (FSHR) negative allosteric modulator (NAM). ADX61623 shows luteinizing hormone receptor (LH-R) activity and is not active on thyroid-stimulating hormone (TSH) receptors. ADX61623 can be used for the study of estrogen dependent disease .
    ADX61623
  • HY-P3975

    pGlu-His-Pro-Gly-NH2

    GnRH Receptor Endocrinology
    Glp-His-Pro-Gly-NH2 (pGlu-His-Pro-Gly-NH2) is a peptide containing 4 amino acids. Glp-His-Pro-Gly-NH2 stimulates gonadotrophin, luteinizing hormone (LH) and follicle stimulating hormone (FSH) release .
    Glp-His-Pro-Gly-NH2
  • HY-P4564

    GnRH Receptor Endocrinology
    (D-Ser(tBu)6,D-Leu7,Azagly10)-LHRH is an analogue of luteinizing hormone-releasing hormone (LHRH). LHRH plays a central role in the control of reproduction by stimulating the release of pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) .
    (D-Ser(tBu)6,D-Leu7,Azagly10)-LHRH
  • HY-P4568

    GnRH Receptor Endocrinology
    (D-Ser4,D-Ser(tBu)6,Azagly10)-LHRH is an analogue of luteinizing hormone-releasing hormone (LHRH). LHRH plays a central role in the control of reproduction by stimulating the release of pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) .
    (D-Ser4,D-Ser(tBu)6,Azagly10)-LHRH
  • HY-P4577

    GnRH Receptor Endocrinology
    (D-Tyr5,D-Ser(tBu)6,Azagly10)-LHRH is an analogue of luteinizing hormone-releasing hormone (LHRH). LHRH plays a central role in the control of reproduction by stimulating the release of pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) .
    (D-Tyr5,D-Ser(tBu)6,Azagly10)-LHRH
  • HY-B0795
    MHY1485
    Maximum Cited Publications
    132 Publications Verification

    mTOR Autophagy Cancer
    MHY1485 is a potent cell-permeable mTOR activator that targets the ATP domain of mTOR. MHY1485 inhibits autophagy by suppression of fusion between autophagosomes and lysosomes .
    MHY1485
  • HY-P3666

    GnRH Receptor Endocrinology
    [D-Phe2,6, Pro3]-LH-RH is a potent luteinizing hormone releasing hormone (LHRH) antagonist .
    [D-Phe2,6, Pro3]-LH-RH
  • HY-18572

    2,4-Dichlorophenoxyacetic acid

    DNA/RNA Synthesis Apoptosis Others
    2,4-D (2, 4-dichlorophenoxyacetic acid) is a selective herbicide that can be orally active for the control of broad-leaved weeds. 2,4-D can induce apoptosis. 2,4-D inhibits DNA and protein synthesis, thereby preventing normal plant growth and development .
    2,4-D
  • HY-P1250

    Neuropeptide VF(124-131)(human); Neuropeptide NPVF (human)

    Neuropeptide Y Receptor Neurological Disease
    RFRP-3 (Neuropeptide VF(124-131))(human), a human GnIH peptide homolog, is a potent inhibitor of gonadotropin secretion by inhibiting Ca 2+?mobilization. RFRP-3(human) is a NPFF1?receptor agonist, it inhibits forskolin-induced production of cAMP with an IC50 of 0.7 nM .
    RFRP-3(human)
  • HY-18572AR

    DNA/RNA Synthesis Apoptosis Others
    2,4-D (sodium salt) (Standard)
  • HY-18572R

    DNA/RNA Synthesis Apoptosis Others
    2,4-D (Standard) is the analytical standard of 2,4-D. This product is intended for research and analytical applications. 2,4-D (2, 4-dichlorophenoxyacetic acid) is a selective herbicide that can be orally active for the control of broad-leaved weeds. 2,4-D can induce apoptosis. 2,4-D inhibits DNA and protein synthesis, thereby preventing normal plant growth and development .
    2,4-D (Standard)
  • HY-107850A

    Allopregnanediol

    GnRH Receptor Endocrinology
    5α-Pregnane-3α,20α-diol (Allopregnanediol) is a derivative of progesterone and is one of the various steroids secreted by the ovaries of rats. 5α-Pregnane-3α,20α-diol can significantly stimulate the release of luteinizing hormone (LH) in castrated rats that have been pre-treated with estrogen, while simultaneously inhibiting the secretion of follicle-stimulating hormone (FSH) .
    5α-Pregnane-3α,20α-diol
  • HY-120767

    KLH-2109 choline; OBE-2109 choline

    GnRH Receptor Inflammation/Immunology Cancer
    Linzagolix choline (KLH-2109 choline) is a non-peptide gonadotropin-releasing hormone (GnRH) antagonist with oral activity. Linzagolix choline inhibits the release of endogenous gonadotropins such as luteinizing hormone LH and follicle-stimulating hormone FSH by binding to the GnRH receptor within the pituitary gland. This inhibition results in a reduction in the production of sex hormones such as estrogen and progesterone, which in turn affects the course of sex hormone-dependent diseases. Linzagolix choline can be used in the study of sex hormone-dependent diseases such as endometriosis and uterine fibroids .
    Linzagolix choline
  • HY-P2161B
    TAK-683 acetate
    1 Publications Verification

    Kisspeptin Receptor Cancer
    TAK-683 acetate is a potent full KISS1 receptor (KISS1R) agonist (IC50=170 pM) with improved metabolic stability. TAK-683 acetate is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC50 values of 0.96 nM and 1.6 nM for human and rat, respectively . TAK-683 acetate depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer .
    TAK-683 acetate
  • HY-P2161

    Kisspeptin Receptor Cancer
    TAK-683 is a potent full KISS1 receptor (KISS1R) agonist (IC50=170 pM) with improved metabolic stability. TAK-683 is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC50 values of 0.96 nM and 1.6 nM for human and rat, respectively . TAK-683 depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer .
    TAK-683
  • HY-P2161A

    Kisspeptin Receptor Cancer
    TAK-683 TFA is a potent full KISS1 receptor (KISS1R) agonist (IC50=170 pM) with improved metabolic stability. TAK-683 TFA is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC50 values of 0.96 nM and 1.6 nM for human and rat, respectively . TAK-683 TFA depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer .
    TAK-683 TFA
  • HY-122179

    TGF-β Receptor Inflammation/Immunology
    NUCC-555 is an activin antagonist. NUCC-555 interacts with Trp25, Trp28, Phe55, Tyr93, Lys103, and Asn107 in the Activin A binding pocket. NUCC-555 blocks Activin A-mediated hepatic stellate cells (HSCs) activation. NUCC-555 promotes liver regeneration and halts fibrosis progression in chronic liver disease models. NUCC-555 inhibits Activin A-mediated ovarian cell proliferation. NUCC-555 decreases FSH levels in ovariectomized mice .
    NUCC-555
  • HY-16474R

    GnRH Receptor Endocrinology Cancer
    Relugolix (Standard) is the analytical standard of Relugolix. This product is intended for research and analytical applications. Relugolix (TAK-385) is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209) . Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al .
    Relugolix (Standard)
  • HY-W011100R

    Dengue Virus Estrogen Receptor/ERR Flavivirus Infection Endocrinology
    Cyclofenil (Standard) is the analytical standard of Cyclofenil. This product is intended for research and analytical applications. Cyclofenil is a selective estrogen receptor modulator and an ovulation-inducing agent. Cyclofenil shows an inhibitory effect on dengue virus replication in Vero cells with an EC50 of 1.62 μM. Cyclofenil has anti-dengue-virus activity .
    Cyclofenil (Standard)
  • HY-W011100

    Dengue Virus Estrogen Receptor/ERR Flavivirus Infection Endocrinology
    Cyclofenil is a selective estrogen receptor modulator and an ovulation-inducing agent. Cyclofenil shows an inhibitory effect on dengue virus replication in Vero cells with an EC50 of 1.62 μM. Cyclofenil has anti-dengue-virus activity .
    Cyclofenil
  • HY-16474

    TAK-385

    GnRH Receptor Endocrinology Cancer
    Relugolix (TAK-385)?is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209) . Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al .
    Relugolix
  • HY-P0037

    Org 30850ANT

    Others GnRH Receptor Endocrinology
    Org-30850 is a potent LHRH antagonist designed for treating hormone-dependent disorders. In animal studies, a single subcutaneous dose effectively inhibited ovulation in rats and significantly reduced testosterone levels in male rats for up to 48 hours post-administration. Daily doses of Org-30850 in female rats suppressed estrous cycles, decreased uterine and ovarian weights, and lowered estradiol and FSH serum levels. In male rats, prolonged treatment resulted in reversible reductions in gonadal function and testosterone levels, with almost complete recovery observed after cessation of treatment. Unlike comparable LHRH antagonists, Org-30850 exhibited minimal injection site irritation and no edematous reactions, suggesting a more favorable therapeutic profile .
    Org-30850

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: